Abstract
Significant advances in understanding of prostate cancer biology induce a rapid development of modern diagnostic tests. Several novel biomarkers have been recently introduced.
However, with regard to current tendencies in the treatment of prostate cancer there is a need for reliable marker discriminating not only between malign and benign prostatic disease but mainly between indolent and aggressive cancer. The following article presents an overview of both established and new promising markers of prostate cancer.
Some of novel biomarkers carry the potential to improve prostate cancer diagnostics and to enable risk stratification in clinical practice.